Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 379

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 379
---
 are committed to providing fast turnaround times, competitive pricing, and logistics expertise to further strengthen our position as the partner of choice; and • Co -development opportunities:we plan to provide our partners with the opportunity to invest in the development of future innovations, driven by the collection of respective localized data and the identification of specific regional needs. This collaborative approach not only accelerates innovation but also allows our partners to directly benefit from the growth and advancements in the genomics industry. This approach is further reinforced by the involvement of consortium members who have chosen to invest in Omnigenics, further solidifying our mutual commitment to shared success and continuous development; Scale existing products internationally Our extensive investment in basic and applied science, as well as deep tech development (e.g., data collection and algorithm training) has positioned us with a robust portfolio of products ready for international expansion. Our initial focus is on Latin America, where we aim to build solidified position across the Americas starting from the following key initiatives: • Develop strategic partnerships in Latin America:over the past decade, we have built strong relationships with commercial and potential partners in the region. Heritas and its founders, as genomics pioneers, have established valuable connections with laboratory operators and international pharmaceutical companies. These relationships provide unique opportunities for market development such as the creation of the consortium; and • Mexico processing hub:Mexico is a strategic point for expending our services, due to the size of the market and the potential benefits it represents for our partners across the region. Our partnerships in place will allow us to establish a wet -labfacility (“Mexican Wet -Lab”) to process and support all commercialized services in the country and the region. 189 Establish a global R&D Hub We are transforming our Argentine operations into our global research and development (“R&D”) hub. Leveraging Argentina’s academic excellence in biology and medicine, access to world -classtechnical talent, and our established reputation in precision medicine, we expect to develop and pilot new products with global potential, with collected omni -modalregional data. We expect this hub to be central to our innovation strategy, driving advancements that is expected to support our international growth. Develop digital profiles in genomics The integration of AI is transformative, unlocking the full potential of genomics in health and disease management. Foundation AI models, which incorporate machine learning techniques, form the backbone of AI technology. These models mimic human cognitive functions such as learning, reasoning, perception, and decision -making, enabling advanced data processing and analysis. They recognize patterns, make predictions, and